Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Core Insights - Apogee Therapeutics is advancing its pipeline with promising interim data for APG808 and APG777, indicating potential for innovative dosing regimens and significant market impact in inflammatory and immunology conditions [2][3][5] Group 1: APG808 Developments - APG808 Phase 1 trial results show it was well-tolerated with a half-life of approximately 55 days, suggesting a potential dosing regimen of every 2- to 3-months, significantly longer than current therapies [3][6] - The trial enrolled 32 healthy adult participants, demonstrating deep and sustained effects on pharmacodynamic markers for up to 3 months [3][6] - Apogee plans to evaluate APG808 in a Phase 1b trial for asthma, with data expected in the first half of 2025 [3][6] Group 2: APG777 Progress - APG777 has shown a half-life of 77 days in its Phase 1 trial, supporting a potential annual dosing schedule, which could disrupt the $50 billion atopic dermatitis market [6][5] - The ongoing Phase 2 trial of APG777 in atopic dermatitis is expected to report 16-week topline data in mid-2025, accelerated due to strong enrollment [6][5] - APG777 is also being developed for eosinophilic esophagitis and asthma, with plans for a Phase 1b trial in asthma in the first half of 2025 [6][5] Group 3: Combination Therapies - Apogee is pursuing first-in-class combination therapies, including APG777 with APG990 and APG333, targeting broader inflammatory pathways for enhanced efficacy [7][8][12] - The APG777 + APG990 combination is expected to enter a Phase 1b trial against DUPIXENT in 2025, with results anticipated in the second half of 2026 [9][8] - APG777 + APG333 is planned for a Phase 1 trial by the end of 2024, aiming to address Type 2 and Type 3 inflammation with potentially less frequent dosing [11][12]